Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : Nifedipine
Therapeutic Area : Pulmonary/Respiratory Diseases
Study Phase : Undisclosed
Sponsor : Pulmodyne
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Undisclosed
Product Name : Undisclosed
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
December 05, 2019
Lead Product(s) : Nifedipine
Therapeutic Area : Pulmonary/Respiratory Diseases
Highest Development Status : Undisclosed
Sponsor : Pulmodyne
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Nifedipine
Therapeutic Area : Obstetrics/Gynecology (Women’s Health)
Study Phase : Phase III
Sponsor : INSERM | Ministry of Health, France | Groupe de Recherche en Obstétrique et Gynécologie
Deal Size : Inapplicable
Deal Type : Inapplicable
Tocolysis in the Management of Preterm Premature Rupture of Membranes Before 34 Weeks of Gestation
Details : Undisclosed
Product Name : Undisclosed
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
June 05, 2019
Lead Product(s) : Nifedipine
Therapeutic Area : Obstetrics/Gynecology (Women’s Health)
Highest Development Status : Phase III
Sponsor : INSERM | Ministry of Health, France | Groupe de Recherche en Obstétrique et Gynécologie
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Nifedipine
Therapeutic Area : Cardiology/Vascular Diseases
Study Phase : Undisclosed
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Undisclosed
Product Name : Undisclosed
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
August 25, 2017
Lead Product(s) : Nifedipine
Therapeutic Area : Cardiology/Vascular Diseases
Highest Development Status : Undisclosed
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Nifedipine
Therapeutic Area : Undisclosed
Study Phase : Phase I
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Undisclosed
Product Name : Undisclosed
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
May 02, 2017
Lead Product(s) : Nifedipine
Therapeutic Area : Undisclosed
Highest Development Status : Phase I
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Nifedipine
Therapeutic Area : Undisclosed
Study Phase : Phase I
Sponsor : BioPharma Services
Deal Size : Inapplicable
Deal Type : Inapplicable
Drug Interaction With Proton Pump Inhibitors for Nifedipine ER Tablets
Details : Undisclosed
Product Name : Undisclosed
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
April 04, 2017
Lead Product(s) : Nifedipine
Therapeutic Area : Undisclosed
Highest Development Status : Phase I
Sponsor : BioPharma Services
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Nifedipine
Therapeutic Area : Cardiology/Vascular Diseases
Study Phase : Phase IV
Sponsor : Bayer AG
Deal Size : Inapplicable
Deal Type : Inapplicable
Nifedipine GITS and Amlodipine Besylate on Recovery of Blood Pressure Rhythm and Arterial Stiffness
Details : Undisclosed
Product Name : Undisclosed
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
October 21, 2016
Lead Product(s) : Nifedipine
Therapeutic Area : Cardiology/Vascular Diseases
Highest Development Status : Phase IV
Sponsor : Bayer AG
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Nifedipine
Therapeutic Area : Cardiology/Vascular Diseases
Study Phase : Phase IV
Sponsor : Bayer AG
Deal Size : Inapplicable
Deal Type : Inapplicable
Effect of Nifedipine GITS in Patients With Mild-to-moderate Primary Hypertension
Details : Undisclosed
Product Name : Undisclosed
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
December 29, 2015
Lead Product(s) : Nifedipine
Therapeutic Area : Cardiology/Vascular Diseases
Highest Development Status : Phase IV
Sponsor : Bayer AG
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Nifedipine
Therapeutic Area : Gastroenterology
Study Phase : Phase II/ Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Undisclosed
Product Name : Undisclosed
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
August 18, 2015
Lead Product(s) : Nifedipine
Therapeutic Area : Gastroenterology
Highest Development Status : Phase II/ Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Nifedipine
Therapeutic Area : Cardiology/Vascular Diseases
Study Phase : Phase IV
Sponsor : Bayer AG
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Undisclosed
Product Name : Undisclosed
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
July 16, 2015
Lead Product(s) : Nifedipine
Therapeutic Area : Cardiology/Vascular Diseases
Highest Development Status : Phase IV
Sponsor : Bayer AG
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Nifedipine
Therapeutic Area : Cardiology/Vascular Diseases
Study Phase : Phase IV
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Undisclosed
Product Name : Undisclosed
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
April 10, 2015
Lead Product(s) : Nifedipine
Therapeutic Area : Cardiology/Vascular Diseases
Highest Development Status : Phase IV
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable